The U.S. Food and Drug Administration's reviewers on Wednesday raised efficacy concerns over the use of Otsuka Pharma's drug ...

An FDA advisory panel concludes that the efficacy of brexpiprazole, when started concurrently with sertraline, has not been ...

The U.S. Food and Drug Administration's panel of independent advisers on Friday voted against the efficacy of Otsuka Pharma's ...

The CAPS-5 total score ranks severity of 20 PTSD symptoms from 0 (not present) to 80 (most severe). Baseline values for the ...

"I may have been swayed if this represented a major advance in the field," said panelist Walter Dunn, MD, PhD, of the ...

This summary covers significant health news including FDA advisers rejecting Otsuka's PTSD treatment, Getinge exceeding ...

Otsuka Pharma (OTCPK:OTSKY) and H. Lundbeck (OTCPK:HLBBF) draws efficacy concerns for their PTSD therapy from the FDA ahead ...

A U.S. Food and Drug Administration (FDA) advisory panel has voted overwhelmingly against the approval of Otsuka ...

The controversial drugs are not yet approved by federal regulators, but advocates hope a NC law would allow the state to be ...

The FDA panel rejects Otsuka's PTSD drug combination. Humana's lawsuit challenging Medicare rating downgrades is dismissed. Spain reports an avian flu outbreak, causing global supply concerns.

An FDA advisory panel will meet July 18 to consider a supplemental new drug application for the antipsychotic brexpiprazole, ...

The U.S. Food and Drug Administration's reviewers have raised efficacy concerns over Otsuka Pharma's combination drug for ...